Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Attention Deficit Disorder With Hyperactivity
Clinical Trial
NCT00626236Last updated: 12/4/2025
SUPN
SUPERNUS PHARMACEUTICALS, INC.
